Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca, a non-covalent Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a BTK inhibitor.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Structure Therapeutics price target lowered to $87 from $91 at Citizens JMP
- Can Telehealth Frontrunner Hims & Hers Health Bounce Back from its Q4 Bombshell?
- Trump Tariffs Are On the Table Once More for Canada & Mexico
- BIOA Lawsuit Alert! Class Action Lawsuit Against BioAge Labs, Inc.
- Eli Lilly (LLY) Commits $27B to U.S. Days after Trump Told Big Pharma to Bring Production Home or Face Tariffs